Gilead Sciences (GILD) boosted its full-year outlook after beating Wall Street's top- and bottom-line expectations. Gilead stock is currently hitting a ceiling at its 50-day line.

During the June quarter, the biotech giant earned an adjusted $2.01 per share on $7.08 billion in sales. Earnings were flat year over year, but topped analysts' call for $1.96, according to FactSet. Sales edged 2% higher and narrowly beat expectations for $6.98 billion.

The results prodded Gilead to toe its 2025 outlook higher. The company now expects to earn $7.95 to $8.25 per share. At the midpoint, that's up 20 cents per share from Gilead's previous guidance.

Gilead also calls for $28.3 billion to $28.7 billion in product sales, which excludes revenue from licensing and collaboration agreements. The new guidance is up $100 million from the outlook Gilead issued three months ago.

Gilead stock is consolidating with a buy point at 119.96, according to MarketSurge. But shares were flat in after-hours trading.

Gilead Stock: Biktarvy Easily Beats

Notably, Gilead's biggest moneymaker, HIV drug Biktarvy, brought in $3.53 billion in sales, up 9% and above forecasts for $3.38 billion. Sales of another HIV drug, Descovy, smashed forecasts at $653 million. Analysts called for just $612 million. Descovy sales shot nearly 35% higher.

Descovy is one of the pre-exposure prophylaxis drugs, or PrEP. It can treat HIV. But it can also help prevent HIV from taking hold in at-risk people.

Gilead also won approval in the quarter for a twice-yearly shot to prevent HIV called Yeztugo. Yeztugo is included in Gilead's "other HIV" segment, which brought in $107 million in sales.

Promisingly, sales of cancer drug Tecartus beat expectations at $92 million. Trodelvy brought in $364 million in sales, growing almost 14% and beating calls for $340 million. But Yescarta came up short at $393 million. Analysts called for a slightly stronger $398 million.

Veklury, Gilead's Covid treatment also came in short at $121 million. Analysts projected $200 million. But it's important to note that it's hard to project sales of Covid-tied items, especially during the summer months.

Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

YOU MAY ALSO LIKE:

Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying

Is Exact Sciences, Down 11%, 'Throwing Good Money At Bad' In Its New Licensing Deal?

Get Timely Buy & Sell Alerts With IBD Leaderboard

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists